All articles by GlobalData Healthcare

Venture financing for mRNA-based vaccines declines 82% in 2025 YTD

Venture financing for messenger ribonucleic acid (mRNA)-based innovator vaccines declined by 82% from $510m in 2023 to $90m in the 2025's…
ERS 2025: Long-term CFTR use shows clinical benefit but variable microbial impact

At the 2025 European Respiratory Society (ERS) International Congress taking place in Amsterdam, the Netherlands, from 27 September to 1…
ERS 2025: APG808 to address need for biologic for moderate asthma

At the 2025 European Respiratory Society (ERS) International Congress takig place in Amsterdam, the Netherlands, from 27 September to 1…
Expanding GLP-1 horizons: Novo Nordisk leads MASH therapeutic race

On 15 August 2025, Novo Nordisk’s Wegovy (semaglutide 2.4mg) received accelerated approval from the US Food and Drug Administration for…
FDA gives first approval for recurrent respiratory papillomatosis therapy

On 14 August 2025, the US Food and Drugs Administration (FDA) approved Precigen’s Papzimeos (zopapogene imadenovec) for recurrent respiratory papillomatosis…

EASD 2025: Alirocumab significantly reduces ischemic events and mortality in ASCVD

On 17 September, at the European Association for the Study of Diabetes (EASD) event in Vienna, findings were presented from…
FDA ends HAE drought with record year of approvals

After four years of inactivity, the US Food and Drug Administration (FDA) approved three novel products for hereditary angiooedema (HAE)…
EASD 2025: NA-931 establishes excellent efficacy and safety in obese patients

At the European Association for the Study of Diabetes (EASD) Annual Meeting 2025, findings from a Phase II clinical trial…
EASD 2025: miR-155 upregulation in pancreas spotlights new T1D targets

At the 2025 European Association for the Study of Diabetes meeting in Vienna, University of Bremen investigators reported that microRNA‑155…
EASD 2025: REDEFINE 2 trial unveils meaningful weight reduction with CagriSema

At the European Association for the Study of Diabetes (EASD) Annual Meeting 2025, findings were shown from the Phase IIIa…